Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Take Amgen's experimental drug MariTide: people lost up to 20% of ... full interview for more from Skovronsky on Lilly's work in obesity and where he sees the market going.

Take Amgen's experimental drug MariTide: people lost up to 20% of ... full interview for more from Skovronsky on Lilly's work in obesity and where he sees the market going. Don't expect a 20% ...